Phaseline

Targets › TCF4

TCF4 (Transcription factor 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Mar 2029.

Transcription factor that binds to the immunoglobulin enhancer Mu-E5/KE5-motif. Involved in the initiation of neuronal differentiation. (UniProt, P15884)

Open in Phaseline: the race on TCF4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mahzi TherapeuticsMZ-1866
AAV-9 gene therapy for TCF4 gene replacement
TCF4Phase 1Pitt Hopkins SyndromeMar 2029

Conditions

Pitt Hopkins Syndrome (1)

Modalities

other (1)

Companies

Mahzi Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.